Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0000950170-23-021245

Principal Accounting Officer sold 210 shares at $3.31 ($695)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Tourangeau Greg Principal Accounting Officer 2023-05-10 Sale −210 $3.31 $695 15,992 D: show line 1 in the form
Open-market sales · 210 sh · avg $3.31 · $695
Loading xslF345X04/ownership.xml…